Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbusters, will go into effect in 2027.

The U.S. Centers for Medicare and Medicaid Services has named Novo Nordisk’s Wegovy, Ozempic and Rybelsus as part of the ...

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

The U.S. government said on Wednesday it will consider opportunities to "bring greater transparency" for the Medicare drug ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

See the 10 stocks » However, the Centers for Medicare and Medicaid Services (CMS) could soon throw a monkey wrench into Novo Nordisk's momentum. The agency announced last week that Ozempic and ...

The two drugs are Novo Nordisk's top growth drivers, and together comprise over 60% of its total revenue. However, the Centers for Medicare and Medicaid Services (CMS) could soon throw a monkey ...